Home / Market News / $PEN

$PEN news and market catalysts

The 4 most recent market catalysts affecting $PEN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

4 catalysts 2 high impact 2 bullish 1 bearish Medical Devices
Oct 29, 2026 Corporate Catalyst Neutral Impact 85
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
Penumbra, Inc. reported strong Q3 2026 results, with revenue up 15.6% and net income of $42.3 million. This performance indicates healthy underlying business operations, particular…
Oct 26, 2026 Corporate Catalyst Bullish Impact 75
Penumbra, Inc. Announces Positive Clinical Results from BOLT-DVT Trial
Penumbra, Inc. (PEN) disclosed highly positive results from its BOLT-DVT clinical trial, showcasing a 98% thrombus removal rate and a low 3.1% major adverse event rate. This is a s…
Oct 20, 2026 Corporate Catalyst Bullish Impact 75
Penumbra Wins FDA Clearance For Lightning CAVT Technology To Treat Deep Vein Thrombosis, Backed By BOLT-DVT Trial Results
Penumbra, Inc. received FDA clearance for its Lightning computer assisted vacuum thrombectomy (CAVT) technology for the treatment of deep vein thrombosis (DVT). This is a significa…
Jul 30, 2026 Corporate Catalyst Bearish Impact 92
Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate
Penumbra's Q2 earnings report reveals a mixed performance. The substantial miss on EPS, down 23.48% year-over-year, is a significant concern for investors, indicating potential iss…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.